Across TCGA pan-cancer cohorts, DEFB110 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DEFB110 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher DEFB110 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB110 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

SCLC, UCEC, and LUAD are the cancer types where DEFB110 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.274	0.711	.008	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: DEFB110 tumor-vs-normal RNA expression · all DEFB110 data types